Home › Colleges & Schools▻College of Medicine, Nursing & Health Sciences▻Staff Profiles

Staff Profiles

Dr. Sharon Glynn

BSc, MPH, PhD.

Contact Details

Lecturer Above The Bar
Pathology
R.3.16
Lambe Institute for Translational Research
School of Medicine
Costello Rd
Galway

T: 091 494242
E: sharon.glynn@nuigalway.ie
W: https://ie.linkedin.com/pub/sharon-glynn/14/1a3/895 https://scholar.google.com/citations?user=pDMH9g0AAAAJ&hl=en
 
researcher

Biography

Dr. Sharon Glynn is Lecturer Above the Bar in Pathology at NUI Galway. She graduated in 1997 with a BSc in Biotechnology (Dublin City University) and in 2003 with a PhD entitled “An investigation of the role of the ErbB receptor family in chemotherapeutic drug resistance and invasion in human breast cancer”  (Dublin City University). After graduation Dr. Glynn served as a research officer at the National Institute for Cellular Biotechnology in Dublin City University where she studied the efficacy of new therapeutics including cholesterol lowering statins on breast cancer and melanoma proliferation and invasion. From 2005 to 2009 Dr. Glynn worked as an NCI Cancer Prevention Fellow in Bethesda Maryland, USA in the Laboratory of Human Carcinogenesis under the mentorship of Dr. Stefan Ambs, studying the role of inflammation pathways in estrogen receptor negative breast cancer progression using an approach combining molecular epidemiology and basic laboratory science. She discovered a novel role for NOS2 in ER negative and basal-like breast cancer progression. Dr. Glynn also discovered a polymorphism in the SOD2 gene predicative of response to cyclophosphamide containing chemotherapeutic regimens in breast cancer cases, receiving an NIH Fellows Award for Research Excellence for this work. In September 2009 Dr. Glynn moved to the Radiation Biology Branch at the NCI, to continue working with Dr. David Wink. During this time Dr. Glynn was awarded a Keystone Symposia Scholarship for her work. From September 2010 to December 2014 Dr. Glynn was the Director of Laboratory Research at the Prostate Cancer Institute at NUI Galway. To date Dr. Glynn has authored over 35 papers in peer reviewed journals and has received numerous grants from Breast Cancer Now UK and the Irish Cancer Society. Dr. Glynn's current work is focused on elucidating the role of inflammation in triple negative breast cancer and metastatic prostate cancer.

Research Interests

Inflammation and Breast and Prostate Cancer
Chronic inflammation and infection are major mediators of cancer initiation and cancer progression. Key mediators of inflammation-induced cancer include NFkB, reactive oxygen and nitrogen species, inflammatory cytokines, prostaglandins and specific microRNAs, which in turn exert their effects though changes in cell proliferation, apoptosis, cellular senescence, DNA mutation rates, DNA methylation, cell invasiveness and angiogenesis. Together these species present the ideal targets for early detection, diagnosis, prediction of outcome and also therapeutic targets. Nitric oxide (NO) the product of nitric oxide synthase 2 (NOS2) can influence tumour biology in various and sometimes dichotomous ways. Genetic ablation of NOS2 increases mammary tumour latency and inhibits lung tumour development in mouse models of cancer. These genetic findings demonstrate that NOS2 can have tumour promoting activities. However, NOS2 expression or other forms of NO exposure are not always tumour promoting, and there are many examples where exposure to NO either delayed or inhibited tumour growth and metastasis. Because the effects of NO are strictly concentration-dependent with high concentrations causing cytostasis and apoptosis, at least some of the observed differences are likely explained by a difference in levels of NO exposure. 
The Prostate Cancer - Bone Marrow Mesenchymal Stem Cells Para-endocrine Axis in the metastatic tumor microenvironment
Mesenchymal stem cells (MSC) are multipotent stem cells that can differentiate into osteoblasts, chondrocytes, adipocytes, myocytes and neurons. They can be sourced from the bone marrow (BM) stroma, adipose tissue and dental pulp, and are also found in circulation and are known to home to inflammatory sites. Due to their capacity to home to injured tissue, research has suggested a reparative function for MSC in multiple tissues.  In recent studies it has been shown that MSC can also home to tumour sites and contribute to tumour growth and progression. MSC have been shown to increase the metastatic potential of tumour cells by promoting their migration and invasion as well as having a role in the development of a metastatic niche at the secondary site. BM-MSC may also contribute to tumour growth by differentiating into cancer associated fibroblasts (CAFs), which form part of the tumour microenvironment. Additionally BM-MSCs are intrinsically radio- and chemo-resistant due to a heightened DNA damage response, and thus may contribute to treatment resistance.  Our preliminary studies demonstrate that considerable baseline variations exist in the secretomes of primary BM-MSCs which impact the magnitude of their response to PrCa cell lines, and vice versa. This indicates that inter-patient BM-MSC variation, may impact on tumour microenvironment dynamics, influencing a patients risk of metastasis, and potentially therapeutic response. Our preliminary data has also identified members of the BM-MSC secretome that induce PrCa cell migration in a dose dependant manner, using recombinant growth factors at the concentrations produced by the BM-MSCs.  
 Human Endogenous Retrovirus Activation in Breast and Prostate Cancer
In recent years scientists have observed that several tumor types, including prostate cancer, show increased expression of human endogenous retrovirus (HERV) when compared to normal tissue. Why are these HERVs of interest? The HERVs originated from germ cell infections by exogenous retroviruses during the course of evolution and became incorporated into the human genome. These elements are widely dispersed throughout the genome and are estimated to comprise of greater than >8% of genomic material. Over 20 HERV families have been identified to date, the majority of which are defective due to mutations, deletions or termination signals within coding regions. The HERV-K family, evolutionarily the youngest HERV, is the only HERV family with complete open reading frames for all viral genes, and thus are the most likely to be biologically active and potentially pathogenic. Several questions need to be asked about HERV-K in prostate cancer. Is HERV-K activation a bystander effect in prostate cancer or is it linked to active prostate progression; can it distinguish indolent from aggressive disease? What is the major activator of HERV-K expression in prostate cancer? Does chronic inflammation in prostate tissues lead to the activation of HERV-K expression or does activation of HERV-K lead to tissue inflammation and subsequent carcinogenesis? Pockets of inflammation are often observed in prostate tissues that are not actually cancerous tissue but are thought to be associated with increased risk of prostate cancer.
 
If interested in pursuing applications for PhD funding, please contact me at sharon.glynn@nuigalway.ie 

Research Projects

  Project Start Date End Date
MOLECULAR IMPACT OF HUMAN ENDOGENOUS RETROVIRUS K ACTIVATION IN BREAST CANCER 01-SEP-16 31-AUG-19
PRECISE- PRostatE Cancer: Improving active SurveillancE 19-JAN-14 21-APR-15
NOS2&COX2 ACTIVATION OF TLR4 AND EGFR SIGNALLING CAUSES POOR OUTCOME IN OESTROGEN RECEPTOR-NEGATIVE BREAST CANCER VIA PRO SURVIVAL SIGNALS AND IMMUNE POLARISATION S GLYNN 03-MAR-14 02-JUN-17
THE PROSTATE CANCER- BONE MARROW MESENCHYMAL STEM CELLS PARADOCRINE AXIS IN THE METASTATIC TUMOR MICROENVIROMENT SHARON GLYNN FRANK SULLIVAN 31-DEC-13 31-MAR-17

Contract Researchers

  Researcher Name Project Role Funding Body
Pablo Garrido Breast Cancer Now Project Grant Postdoctoral Researcher Other

Peer Reviewed Journals

  Year Publication
(2017) 'Inflammation and Nitrosative Stress Effects in Ovarian and Prostate Pathology and Carcinogenesis'
Burke AJ, Garrido P, Johnson C, Sullivan FJ, Glynn SA. (2017) 'Inflammation and Nitrosative Stress Effects in Ovarian and Prostate Pathology and Carcinogenesis'. Antioxidants & Redox Signaling, [DOI] [Details]
(2017) 'Mesenchymal stem cells: key players in cancer progression'
Ridge SM, Sullivan FJ, Glynn SA. (2017) 'Mesenchymal stem cells: key players in cancer progression'. Molecular Cancer, 16 (1) [DOI] [Details]
(2016) 'Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression'
Basudhar D, Somasundaram V, de Oliveira GA, Kesarwala A, Heinecke JL, Cheng RY, Glynn SA, Ambs S, Wink DA, Ridnour LA. (2016) 'Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression'. Antioxid Redox Signal, [Details]
(2016) 'Sensitivity Profiles of Human Prostate Cancer Cell Lines to an 80 Kinase Inhibitor Panel'
Burke, AJ,Ali, H,O'Connell, E,Sullivan, FJ,Glynn, SA (2016) 'Sensitivity Profiles of Human Prostate Cancer Cell Lines to an 80 Kinase Inhibitor Panel'. Anticancer Research, 36 :633-641 [Details]
(2016) 'An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers'
Prueitt, RL,Wallace, TA,Glynn, SA,Yi, M,Tang, W,Luo, J,Dorsey, TH,Stagliano, KE,Gillespie, JW,Hudson, RS,Terunuma, A,Shoe, JL,Haines, DC,Yfantis, HG,Han, M,Martin, DN,Jordan, SV,Borin, JF,Naslund, MJ,Alexander, RB,Stephens, RM,Loffredo, CA,Lee, DH,Putluri, N,Sreekumar, A,Hurwitz, AA,Ambs, S (2016) 'An Immune-Inflammation Gene Expression Signature in Prostate Tumors of Smokers'. Cancer Research, 76 :1055-1065 [DOI] [Details]
(2014) 'Gene expression profiles of NO- and HNO-donor treated breast cancer cells: insights into tumor response and resistance pathways'
Cheng, RYS,Basudhar, D,Ridnour, LA,Heinecke, JL,Kesarwala, AH,Glynn, S,Switzer, CH,Ambs, S,Miranda, KM,Wink, DA (2014) 'Gene expression profiles of NO- and HNO-donor treated breast cancer cells: insights into tumor response and resistance pathways'. Nitric Oxide-Biology And Chemistry, 43 :17-28 [DOI] [Details]
(2015) 'Human endogenous retrovirus K and cancer: Innocent bystander or tumorigenic accomplice?'
Downey, RF,Sullivan, FJ,Wang-Johanning, F,Ambs, S,Giles, FJ,Glynn, SA (2015) 'Human endogenous retrovirus K and cancer: Innocent bystander or tumorigenic accomplice?'. International Journal Of Cancer, 137 :1249-1257 [DOI] [Details]
(2015) 'Signaling and stress: The redox landscape in NOS2 biology'
Thomas DD, Heinecke JL, Ridnour LA, Cheng RY, Kesarwala AH, Switzer CH, McVicar DW, Roberts DD, Glynn S, Fukuto JM, Wink DA, Miranda KM. (2015) 'Signaling and stress: The redox landscape in NOS2 biology'. Free Radical Biology And Medicine, 87 :204-225 [DOI] [Details]
(2015) 'A close connection between the PERK and IRE arms of the UPR and the transcriptional regulation of autophagy'
Deegan, S,Koryga, I,Glynn, SA,Gupta, S,Gorman, AM,Samali, A (2015) 'A close connection between the PERK and IRE arms of the UPR and the transcriptional regulation of autophagy'. Biochemical And Biophysical Research Communications, 456 :305-311 [DOI] [Details]
(2014) 'Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers'
Wallace, TA,Downey, RF,Seufert, CJ,Schetter, A,Dorsey, TH,Johnson, CA,Goldman, R,Loffredo, CA,Yan, PS,Sullivan, FJ,Giles, FJ,Wang-Johanning, F,Ambs, S,Glynn, SA (2014) 'Elevated HERV-K mRNA expression in PBMC is associated with a prostate cancer diagnosis particularly in older men and smokers'. Carcinogenesis, 35 :2074-2083 [DOI] [Details]
(2014) 'Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression'
Heinecke, JL,Ridnour, LA,Cheng, RYS,Switzer, CH,Lizardo, MM,Khanna, C,Glynn, SA,Hussain, SP,Young, HA,Ambs, S,Wink, DA (2014) 'Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression'. Proceedings Of The National Academy Of Sciences Of The United States Of America, 111 :6323-6328 [DOI] [Details]
(2013) 'Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment-Poor Prognosis or New Therapeutic Opportunity'
Ridnour, LA,Cheng, RYS,Switzer, CH,Heinecke, JL,Ambs, S,Glynn, S,Young, HA,Trinchieri, G,Wink, DA (2013) 'Molecular Pathways: Toll-like Receptors in the Tumor Microenvironment-Poor Prognosis or New Therapeutic Opportunity'. Clinical Cancer Research, 19 :1340-1346 [DOI] [Details]
(2013) 'The yin and yang of nitric oxide in cancer progression'
Burke, AJ,Sullivan, FJ,Giles, FJ,Glynn, SA (2013) 'The yin and yang of nitric oxide in cancer progression'. Carcinogenesis, :503-512 [DOI] [Details]
(2013) 'Development and Progress of Ireland's Biobank Network: Ethical, Legal, and Social Implications (ELSI), Standardized Documentation, Sample and Data Release, and International Perspective'
Mee B, Gaffney E, Glynn SA, Donatello S, Carroll P, Connolly E, Garrigle SM, Boyle T, Flannery D, Sullivan FJ, McCormick P, Griffin G, Muldoon C, Fay J, O'Grady T, Kay E, Eustace J, Burke L, Sheikh AA, Finn S, Flavin R, Giles FJ. (2013) 'Development and Progress of Ireland's Biobank Network: Ethical, Legal, and Social Implications (ELSI), Standardized Documentation, Sample and Data Release, and International Perspective'. Biopreservation And Biobanking, 11 (1):3-11 [Details]
(2013) 'The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance'
Toner AP, McLaughlin F, Giles FJ, Sullivan FJ, O'Connell E, Carleton LA, Breen L, Dunne G, Gorman AM, Lewis JD, Glynn SA. (2013) 'The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance'. British Journal Of Cancer, [Details]
(2012) 'S-Nitrosation Mediates Multiple Pathways That Lead to Tumor Progression in Estrogen Receptor-Negative Breast Cancer'
Switzer CH, Ridnour LA, Cheng R, Heinecke J, Burke A, Glynn S, Ambs S, Wink DA (2012) 'S-Nitrosation Mediates Multiple Pathways That Lead to Tumor Progression in Estrogen Receptor-Negative Breast Cancer'. Forum on immunopathological diseases and therapeutics, 3 (2):117-124 [DOI] [Details]
(2012) 'Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors'
Wang-Johanning F, Rycaj K, Plummer JB, Li M, Yin B, Frerich K, Garza JG, Shen J, Lin K, Yan P, Glynn SA, Dorsey TH, Hunt KK, Ambs S, Johanning GL (2012) 'Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors'. Journal Of The National Cancer Institute, 104 (3):189-210 [DOI] [Details]
(2012) 'Dithiolethiones inhibit NF-κB activity via covalent modification in human estrogen receptor-negative breast cancer'
Switzer CH, Cheng RY, Ridnour LA, Murray MC, Tazzari V, Sparatore A, Del Soldato P, Hines HB, Glynn SA, Ambs S, Wink DA (2012) 'Dithiolethiones inhibit NF-κB activity via covalent modification in human estrogen receptor-negative breast cancer'. Cancer Research, 72 (9):2394-2404 [DOI] [Details]
(2012) 'Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer'
Switzer, CH,Cheng, RYS,Ridnour, LA,Glynn, SA,Ambs, S,Wink, DA (2012) 'Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer'. Breast Cancer Research, 14 [DOI] [Details]
(2013) 'MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer'
Hudson RS, Yi M, Esposito D, Glynn SA, Starks AM, Yang Y, Schetter AJ, Watkins SK, Hurwitz AA, Dorsey TH, Stephens RM, Croce CM, Ambs S. (2013) 'MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer'. Oncogene, 32 (35):4139-4147 [Details]
(2012) 'S-Nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer'
Switzer S, Glynn SA, Cheng RYS, Ridnour LA,Green JE, Ambs A,Wink DA (2012) 'S-Nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer'. Molecular Cancer Research, 10 (9):1203-1215 [Details]
(2012) 'Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation'
Ridnour LA, Barasch KM, Windhausen AN, Dorsey TH, Lizardo MM, Yfantis HG, Lee DH, Switzer CH, Cheng RY, Heinecke JL, Brueggemann E, Hines HB, Khanna C, Glynn SA, Ambs S, Wink DA (2012) 'Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation'. Plos One, 7 (9) [DOI] [Details]
(2011) 'The specificity of nitroxyl chemistry is unique among nitrogen oxides in biological systems'
Flores-Santana W, Salmon DJ, Donzelli S, Switzer CH, Basudhar D, Ridnour L, Cheng R, Glynn SA, Paolocci N, Fukuto JM, Miranda KM, Wink DA (2011) 'The specificity of nitroxyl chemistry is unique among nitrogen oxides in biological systems'. Antioxidants & Redox Signaling, 14 (9):1659-1674 [DOI] [Details]
(2011) 'Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer'
Switzer, C.H., Glynn, S.A., Ridnour, L.A., Cheng, R.Y.-S., Vitek, M.P., Ambs, S., Wink, D.A. (2011) 'Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer'. Trends in Pharmacological Sciences, 32 (11):644-651 [Details]
(2011) 'Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer'
Ambs, S,Glynn, SA (2011) 'Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer'. Cell Cycle, 10 :619-624 [DOI] [Details]
(2011) 'Expression of Human Endogenous Retrovirus Type K Envelope Protein is a Novel Candidate Prognostic Marker for Human Breast Cancer'
Zhao J, Rycaj K, Geng S, Li M, Plummer JB, Yin B, Liu H, Xu X, Zhang Y, Yan Y, Glynn SA, Dorsey TH, Ambs S, Johanning GL, Gu L, Wang-Johanning F (2011) 'Expression of Human Endogenous Retrovirus Type K Envelope Protein is a Novel Candidate Prognostic Marker for Human Breast Cancer'. Genes & Cancer, 2 (9):914-922 [DOI] [Details]
(2010) 'COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer'
Glynn SA, Prueitt RL, Ridnour LA, Boersma BJ, Dorsey TM, Wink DA, Goodman JE, Yfantis HG, Lee DH, Ambs S (2010) 'COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer'. BMC Cancer, 10 [DOI] [Details]
(2010) 'Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients'
Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, Martin DN, Switzer CH, Hudson RS, Wink DA, Lee DH, Stephens RM, Ambs S (2010) 'Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients'. J Clin Invest, 120 (11):3843-3854 [DOI] [Details]
(2009) 'A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide'
Glynn SA, Boersma BJ, Howe TM, Edvardsen H, Geisler SB, Goodman JE, Ridnour LA, Lønning PE, Børresen-Dale AL, Naume B, Kristensen VN, Chanock SJ, Wink DA, Ambs S (2009) 'A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide'. Clinical Cancer Research, 15 (12):4165-4173 [DOI] [Details]
(2008) 'The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells'
Glynn SA, O'Sullivan D, Eustace AJ, Clynes M, O'Donovan N (2008) 'The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells'. BMC Cancer, 8 [DOI] [Details]
(2007) 'Purification and identification of a 7.6-kDa protein in media conditioned by superinvasive cancer cells'
Dowling P, Maurya P, Meleady P, Glynn SA, Dowd AJ, Henry M, Clynes M (2007) 'Purification and identification of a 7.6-kDa protein in media conditioned by superinvasive cancer cells'. Anticancer Research, 27 (3A):1309-1317 [Details]
(2007) 'Proteomic analysis of isolated membrane fractions from superinvasive cancer cells'
Dowling P, Meleady P, Dowd A, Henry M, Glynn S, Clynes M (2007) 'Proteomic analysis of isolated membrane fractions from superinvasive cancer cells'. Biochimica Et Biophysica Acta, 1774 (1):93-101 [DOI] [Details]
(2006) 'Low adhesiveness coupled with high superinvasiveness in vitro predicts the in vivo metastatic potential of a mouse mammary adenocarcinoma cell line'
Glynn SA, Adams A, Gibson B, Cronin D, Harmey JH, Clynes M (2006) 'Low adhesiveness coupled with high superinvasiveness in vitro predicts the in vivo metastatic potential of a mouse mammary adenocarcinoma cell line'. Anticancer Research, 26 (2A):1001-1010 [Details]
(2004) 'A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin'
Glynn SA, Gammell P, Heenan M, O'Connor R, Liang Y, Keenan J, Clynes M (2004) 'A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin'. Br J Cancer, 91 (10):1800-1807 [DOI] [Details]
(2004) 'Expression and prognostic relevance of Mcl-1 in breast cancer'
O'Driscoll L, Cronin D, Kennedy SM, Purcell R, Linehan R, Glynn S, Larkin A, Scanlon K, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Clynes M (2004) 'Expression and prognostic relevance of Mcl-1 in breast cancer'. Anticancer Research, 24 (2A):473-482 [Details]
(2003) 'Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer'
O'Driscoll L, Linehan R, M Kennedy S, Cronin D, Purcell R, Glynn S, W McDermott E, D Hill A, J O'Higgins N, Parkinson M, Clynes M (2003) 'Lack of prognostic significance of survivin, survivin-deltaEx3, survivin-2B, galectin-3, bag-1, bax-alpha and MRP-1 mRNAs in breast cancer'. Cancer Lett, 201 (2):225-236 [Details]

Book Chapters

  Year Publication
(2014) 'Mechanisms of Nitric Oxide Dependent Regulation of Tumour Invasion and Metastasis'
Ryan AE, Burke AJ, Sullivan FJ, Glynn SA (2014) 'Mechanisms of Nitric Oxide Dependent Regulation of Tumour Invasion and Metastasis' In: ‘NO and Cancer’ - Prognosis, Prevention and Therapy. USA: Springer. [Details]

Conference Publications

  Year Publication
(2014) Irish Association for Cancer Research
Ali, H; Burke, A; O’Connell, E; Giles, FJ; Sullivan, F; Glynn, S. (2014) Novel Kinase Inhibitors as Drug Targets in Prostate Cancer Irish Association for Cancer Research [Details]
(2014) Irish Association for Cancer Research
Toner, AP; Giles, FJ; Carleton, LA; O’Connell, E; Harte, E; Breen, L; Dunne. G; Clynes, M; Lewis, JD; Gorman, AM; Sullivan, FJ; Glynn, SA. (2014) Characterisation of a new class of prostate cancer chemotherapeutics Irish Association for Cancer Research [Details]
(2013) Academic Screening Workshop
Toner, AP; Burke, A; Giles, FJ; Harte, E; Carleton, LA; O’Connell, E; Lewis, JD; Glynn, SA. (2013) Preclicincal analysis of EL102, a novel compound proposed for the treatment of prostate cancer Academic Screening Workshop Baltimore, MD, USA, [Details]
(2013) British Association of Urological Surgeons AGM
Toner, AP; McLaughlin, F; Giles, FJ; Sullivan, FJ; O’Connell, E; Carleton, LA; Breen, L; Gorman , AM; Lewis, JD and Glynn, SA. (2013) Introducing Novel Toluidine Sulphonamide EL102: A Potential Chemotherapeutic In Prostate Cancer British Association of Urological Surgeons AGM [Details]
(2012) Royal Academy of Medicine in Ireland Annual Meeting
Burke, AJ; O'Connell, E; Miranda, KM; Giles, FJ; Sullivan, F; Glynn, SA (2012) Nitric Oxide and its effects on cellular proliferation and phenotype in prostate cancer Royal Academy of Medicine in Ireland Annual Meeting NUI Galway, Ireland, [Details]

Conference Contributions

  Year Publication
(2016) Regulatory effects of NOS2-COX2 in breast cancer progression in tumor microenvironment,
Basudhar, D,Somasundaram, V,Glynn, S,Ridnour, LA,Cheng, RY,Wink, DA (2016) INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE. Regulatory effects of NOS2-COX2 in breast cancer progression in tumor microenvironment, . [Details]

Abstract

  Year Publication
(2015) Human endogenous retrovirus K expression as a possible adjunct to PSA in the diagnosis of prostate cancer.
Downey, R,Murillo, L,McHale, T,Wallace, T,Seufert, C,Schetter, A,Dorsey, T,Johnson, C,Goldman, R,Loffredo, C,Yan, PS,Sullivan, F,Giles, F,Wang-Johanning, F,Ambs, S,Glynn, S (2015) Human endogenous retrovirus K expression as a possible adjunct to PSA in the diagnosis of prostate cancer. Abstract [DOI] [Details]
(2014) Nitric oxide and breast cancer disease progression: Role of timp-1 in pro-survival signaling.
Ridnour, L,Glynn, S,Barasch, K,Windhausen, A,Sneha, D,Dorsey, T,Yfantis, H,Lee, DH,Heinecke, J,Brueggemann, E,Lizardo, M,Khanna, C,Ambs, S,Wink, D,Hines, H,Switzer, C (2014) Nitric oxide and breast cancer disease progression: Role of timp-1 in pro-survival signaling. Abstract [DOI] [Details]
(2013) Cellular fate assessment in triple negative breast cancer (TNBC) predictchemoresponse and patient outcome.
O'Reilly, EA,Sharma, S,Klinger, R,Harrison, M,Weiner-Gorzel, K,Kelly, C,Maguire, A,McCormack, J,Conlon, S,Aherne, S,Beggan, C,Bambury, R,Lyons, T,Dorsey, TH,Ambs, S,O'Connor, D,Quinn, C,McCaffrey, J,Salman, R,Glynn, SA,Furlong, F,McCann, A,Kell, M (2013) Cellular fate assessment in triple negative breast cancer (TNBC) predictchemoresponse and patient outcome. Abstract [Details]
(2014) LDR Brachytherapy in the Management of Patients wih Localized Prostate Cancer: Update of the Galway Experience in the first 536 cases, 2007-2012.
Sullivan, FJ,Walsh, K,Rogers, E,Durkan, G,O'Malley, P,Hayes, DB,O'Boyle, G,Zuchora, A,Woulfe, P,Glynn, S (2014) LDR Brachytherapy in the Management of Patients wih Localized Prostate Cancer: Update of the Galway Experience in the first 536 cases, 2007-2012. Abstract [Details]
(2014) Prostate Cancer Mediated Differentiation of Bone-Marrow Derived Mesenchymal Stem Cells Facilitates Prostate Cancer Cell Invasive and Migratory Capacity.
Ridge, M,Ridge, SM,Ryan, AE,Finn, S,O'Leary, J,Giles, FJ,Sullivan, FJ,Glynn, SA (2014) Prostate Cancer Mediated Differentiation of Bone-Marrow Derived Mesenchymal Stem Cells Facilitates Prostate Cancer Cell Invasive and Migratory Capacity. Abstract [Details]
(2014) The potential of peripheral blood HERV-K expression as a biomarker for diagnosis with prostate cancer in older men.
Glynn, SA,Wallace, T,Downey, R,Seufert, C,Schetter, A,Giles, FJ,Sullivan, F,Dorsey, T,Goldman, R,Yan, PS,Wang-Johanning, F,Ambs, S (2014) The potential of peripheral blood HERV-K expression as a biomarker for diagnosis with prostate cancer in older men. Abstract [Details]
(2014) Further preclinical assessment of compound EL102 in the treatment of prostate cancer.
Toner, AP,Giles, FJ,Sullivan, F,Harte, E,Carleton, LA,Gorman, AM,Lewis, J,Glynn, SA (2014) Further preclinical assessment of compound EL102 in the treatment of prostate cancer. Abstract [Details]
(2014) Human Endogenous Retrovirus K Expression Predicts a Prostate Cancer Diagnosis.
Downey, RF,Wallace, T,Sullivan, FJ,Wang-Johanning, F,Walsh, K,Durkan, G,Rogers, E,Goldman, R,Ambs, S,Glynn, SA (2014) Human Endogenous Retrovirus K Expression Predicts a Prostate Cancer Diagnosis. Abstract [Details]
(2014) Bone Marrow Derived-Mesenchymal Stem Cell Reprogramming by Prostate Cancer Cells to Promote Prostate Cancer Progression.
Ridge, S,O'Leary, K,Shaw, G,Murphy, M,Walsh, K,Durkan, G,Rogers, E,Sullivan, FJ,Glynn, SA (2014) Bone Marrow Derived-Mesenchymal Stem Cell Reprogramming by Prostate Cancer Cells to Promote Prostate Cancer Progression. Abstract [Details]
(2014) Elevated HERV-K Expression in PBMC is Associated with a Diagnosis of Prostate Cancer among Older Men and Current Smokers.
Glynn, A,Downey, R,Wallace, T,Sullivan, FJ,Giles, FJ,Walsh, K,Durkan, G,Roger, E,Wang-Johanning, F,Ambs, S,Glynn, SA (2014) Elevated HERV-K Expression in PBMC is Associated with a Diagnosis of Prostate Cancer among Older Men and Current Smokers. Abstract [Details]

Meeting

  Year Publication
(2013) Introducing novel toluidine sulfonamide EL102, a potential chemotherapeutic in prostate cancer.
Toner, A,Giles, FJ,Sullivan, FJ,Walsh, K,Durkan, G,Rogers, E,Lewis, JD,Glynn, SA (2013) Introducing novel toluidine sulfonamide EL102, a potential chemotherapeutic in prostate cancer. Meeting [Details]
(2012) Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro.
Glynn, SA,Toner, A,Lewis, J,Sullivan, F,Breen, L,Clynes, M,Giles, FJ (2012) Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro. Meeting [Details]

Honours and Awards

  Year Title Awarding Body
2015 Breast Cancer Now PhD Grant Breast Cancer Now
2013 Breast Cancer Campaign Project Grant Breast Cancer Campaign
2013 Irish Cancer Society Prostate Cancer Transformative Programme Grant Irish Cancer Society
2010 Keystone Symposia Scholarship Keystone Symposia
2010 Prostate Cancer Research Award NUI Galway
2009 NIH Fellows Award for Research Excellence National Institutes of Health
2005 All-Ireland Cancer Consortium NCI Cancer Prevention Fellowship NCI, USA & HRB, Ireland

Professional Associations

  Association Function From / To
European Association for Cancer Research Member /
American Association for Cancer Research Member /
Irish Association for Cancer Research Member 01-SEP-97 /

Employment

  Employer Position From / To
National Cancer Institute, USA NCI Cancer Prevention Fellow 01-SEP-05 / 31-MAY-09
National Cancer Institute, USA Visiting Fellow 01-JUN-09 / 31-AUG-10

Education

  Year Institution Qualification Subject
2006 University College Dublin Master in Public Health Public Health
1997 Dublin City University BSc (Hons) Biotechnology
2003 Dublin City University PhD Biotechnology

Recent Postgraduate Students

  Graduation Name Degree Primary Supervisor
2016 Amy Burke PhD Y
2015 Aidan Toner PhD Y
2016 Ronan Downey PhD Y
2016 Sarah Ridge PhD Y

Current Postgraduate Students (Research)

  Student Degree Type Type
Husnain Ali Doctorate - Structured Ph.D (Medicine) Supervisor
Eoin Dervan Doctorate - Structured Ph.D (Medicine) Supervisor
Dibyangana Bhattacharyya Doctorate - Structured Ph.D (Medicine) Supervisor
Carol Johnson Doctorate - Structured Ph.D (Medicine) Supervisor

Modules Taught

  Term/Year Module Title Module Code Subject / Desc
2012/2013 Cancer Research: Technologies and Skills BI462 Methodologies for cancer research
Since 2015 Health and Disease II MD302 Pathology
Since 2015 Health and Disease I MD201 Pathology
2012/2013 Clinical Oncology, Haematology BI461: Lung and genitourinary cancers
2013/2014 Clinical Oncology, Haematology BI461 Lung and genitourinary cancers
2013/2014 Cancer Research: Technologies and Skills BI462 Cancer Research Methodologies
2014/2015 Cancer Research: Technologies and Skills BI462 Cancer research methodologies